Patient demographics and baseline characteristics
| Parameter . | Moxetumomab pasudotox (n = 55) . | |
|---|---|---|
| No. . | % . | |
| Age, y | ||
| Median | 13 | |
| Range | 1-25 | |
| Age category, y | ||
| ≤3 | 4 | 7 |
| >3 to ≤12 | 21 | 38 |
| >12 to ≤19 | 21 | 38 |
| >19 | 9 | 16 |
| Male sex | 31 | 56 |
| Race | ||
| White | 45 | 82 |
| Black | 7 | 13 |
| Asian | 1 | 2 |
| Other | 2 | 4 |
| Ethnicity | ||
| Hispanic | 13 | 24 |
| Non-Hispanic | 42 | 76 |
| Time from diagnosis to study entry, months | ||
| Median | 29 | |
| Range | 7-145 | |
| ECOG performance status (≥12 y) | n = 32 | |
| 0 | 5 | 9 |
| 1 | 15 | 27 |
| 2 or 3 | 8 | 15 |
| Lansky scale score (<12 y) | n = 20 | |
| Normal range | 18 | 33 |
| Mild to moderate restriction | 2 | 24 |
| Prior treatment | ||
| Chemotherapy | 55 | 100 |
| Transplantation | 26 | 47 |
| Radiation therapy | 10 | 18 |
| Biologic | 3 | 6 |
| Other | 8 | 15 |
| Parameter . | Moxetumomab pasudotox (n = 55) . | |
|---|---|---|
| No. . | % . | |
| Age, y | ||
| Median | 13 | |
| Range | 1-25 | |
| Age category, y | ||
| ≤3 | 4 | 7 |
| >3 to ≤12 | 21 | 38 |
| >12 to ≤19 | 21 | 38 |
| >19 | 9 | 16 |
| Male sex | 31 | 56 |
| Race | ||
| White | 45 | 82 |
| Black | 7 | 13 |
| Asian | 1 | 2 |
| Other | 2 | 4 |
| Ethnicity | ||
| Hispanic | 13 | 24 |
| Non-Hispanic | 42 | 76 |
| Time from diagnosis to study entry, months | ||
| Median | 29 | |
| Range | 7-145 | |
| ECOG performance status (≥12 y) | n = 32 | |
| 0 | 5 | 9 |
| 1 | 15 | 27 |
| 2 or 3 | 8 | 15 |
| Lansky scale score (<12 y) | n = 20 | |
| Normal range | 18 | 33 |
| Mild to moderate restriction | 2 | 24 |
| Prior treatment | ||
| Chemotherapy | 55 | 100 |
| Transplantation | 26 | 47 |
| Radiation therapy | 10 | 18 |
| Biologic | 3 | 6 |
| Other | 8 | 15 |
ECOG, Eastern Cooperative Oncology Group.